Founding Motivation
The company was established in August 2011 for commercialization through technology transfer and collaborative research on "viral infection treatments" with the Korean Biotechnology Research Institute.
Main Business Areas
Bioten Co., Ltd. has developed “Tencumin S Plus and Tencumin G Plus” through collaborative research with the government-funded Korean Biotechnology Research Institute, utilizing natural substances solubilized with our patented equipment (10-1894087).
Clinical pharmacology research results of “Tencumin S Plus” showed an absorption rate and persistence in the body that are 400 to 1,000 times greater than existing phytochemicals.
Having demonstrated effective treatment against the PED coronavirus, a major cause of swine diseases, the product was commercialized as a feed additive for the livestock market. We are currently focusing on subsequent research for its development as a veterinary drug.
Especially in preclinical studies, we achieved exceptional results in immune restoration and inflammation reduction. Additionally, we demonstrated excellent therapeutic efficacy in cancer models and have proceeded with the launch of health foods through ongoing PK studies.
In 2021, we successfully became profitable by achieving approximately KRW 6 billion in sales through developing four types of health foods (Inflammation, Immunity, Gut Health, and Inner Beauty) utilizing Tencumin S/G Plus. In 2022, we completed Food and Drug Administration (FDA) approval for five types of foods (Body Fat, Menopause, Diabetes, Liver, and Eye Health), including coffee that reduces fat. We achieved sales of over KRW 10 billion and garnered an operating profit of KRW 1.7 billion.
As a notable achievement, in December 2021, the animal trials for “Tencumin S Plus” showed over a 30% treatment effect in severe infection cases for COVID-19. Not only did it inhibit the 3CL protease in a concentration-dependent manner, but it also exhibited excellent results in restoring immunity, and we are currently conducting toxicity tests for clinical approval.
Bioten Co., Ltd. aims to improve bioavailability through the solubilization of existing drugs. Our strategy focuses on developing natural material-based products, functional healthy foods, veterinary medicines, and, ultimately, human pharmaceuticals.
